Brand Names for GLP-1 and GIP/GLP-1 Receptor Agonists
The brand names for these medications are: liraglutide is marketed as Victoza® (for diabetes) and Saxenda® (for obesity), semaglutide as Ozempic® (for diabetes) and Wegovy® (for obesity), and tirzepatide as Mounjaro® (for diabetes) and Zepbound® (for obesity). 1
Liraglutide Brand Names
- Victoza® (Novo Nordisk): FDA-approved for type 2 diabetes at doses up to 1.8 mg daily 1, 2
- Saxenda® (Novo Nordisk): FDA-approved for chronic weight management at 3.0 mg daily in patients ≥12 years of age 3, 4
Both formulations are once-daily subcutaneous injections with a 13-hour half-life 5.
Semaglutide Brand Names
- Ozempic® (Novo Nordisk): FDA-approved for type 2 diabetes as once-weekly subcutaneous injection at doses of 1 mg and 2 mg 1
- Wegovy® (Novo Nordisk): FDA-approved for obesity management at 2.4 mg once weekly, approved for adults in 2021 and adolescents ≥12 years in 2022 6
- Rybelsus®: Oral formulation approved for type 2 diabetes at 14 mg daily 7
The subcutaneous formulation has a half-life of 183 hours, enabling once-weekly dosing 5.
Tirzepatide Brand Names
- Mounjaro® (Eli Lilly): FDA-approved for type 2 diabetes in May 2022 1, 8
- Zepbound® (Eli Lilly): FDA-approved for obesity management in November 2023 1, 6
Both are once-weekly subcutaneous injections with a half-life of approximately 5 days 8.
Important Clinical Distinction
The diabetes-indicated brands (Victoza®, Ozempic®, Mounjaro®) and obesity-indicated brands (Saxenda®, Wegovy®, Zepbound®) contain the same active ingredients but are approved at different doses for different indications. 7 Insurance coverage is typically restricted to the FDA-approved indication, meaning diabetes brands may not be covered for obesity treatment alone 7.